SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer - PubMed (original) (raw)
. 2003 May 15;22(19):2972-83.
doi: 10.1038/sj.onc.1206474.
Affiliations
- PMID: 12771949
- DOI: 10.1038/sj.onc.1206474
SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer
Constanze Zeller et al. Oncogene. 2003.
Abstract
Loss of heterozygosity (LOH) and in silico expression analysis were applied to identify genes significantly downregulated in breast cancer within the genomic interval 6q23-25. Systematic comparison of candidate EST sequences with genomic sequences from this interval revealed the genomic structure of a potential target gene on 6q24.3, which we called SAM and SH3 domain containing 1 (SASH1). Loss of the gene-internal marker D6S311, found in 30% of primary breast cancer, was significantly correlated with poor survival and increase in tumor size. Two SASH1 transcripts of approximately 4.4 and 7.5 kb exist and are predominantly transcribed in the human breast, lung, thyroid, spleen, placenta and thymus. In breast cancer cell lines, SASH1 is only expressed at low levels. SASH1 is downregulated in the majority (74%) of breast tumors in comparison with corresponding normal breast epithelial tissues. In addition, SASH1 is also downregulated in tumors of the lung and thyroid. Analysis of the protein domain structure revealed that SASH1 is a member of a recently described family of SH3/SAM adapter molecules and thus suggests a role in signaling pathways. We assume that SASH1 is a new tumor suppressor gene possibly involved in tumorigenesis of breast and other solid cancers. We were unable to find mutations in the coding region of the gene in primary breast cancers showing LOH within the critical region. We therefore hypothesize that other mechanisms as for instance methylation of the promoter region of SASH1 are responsible for the loss of expression of SASH1 in primary and metastatic breast cancer.
Similar articles
- Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A. Cvetkovic D, et al. Gynecol Oncol. 2004 Dec;95(3):449-55. doi: 10.1016/j.ygyno.2004.08.051. Gynecol Oncol. 2004. PMID: 15581945 - Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors.
Bilanges B, Varrault A, Basyuk E, Rodriguez C, Mazumdar A, Pantaloni C, Bockaert J, Theillet C, Spengler D, Journot L. Bilanges B, et al. Oncogene. 1999 Jul 8;18(27):3979-88. doi: 10.1038/sj.onc.1202933. Oncogene. 1999. PMID: 10435621 - Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer.
Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B, Janssen KP. Rimkus C, et al. Br J Cancer. 2006 Nov 20;95(10):1419-23. doi: 10.1038/sj.bjc.6603452. Epub 2006 Oct 31. Br J Cancer. 2006. PMID: 17088907 Free PMC article. - Chromosome 3p and breast cancer.
Yang Q, Yoshimura G, Mori I, Sakurai T, Kakudo K. Yang Q, et al. J Hum Genet. 2002;47(9):453-9. doi: 10.1007/s100380200064. J Hum Genet. 2002. PMID: 12202982 Review. - The emerging and diverse roles of the SLy/SASH1-protein family in health and disease-Overview of three multifunctional proteins.
Jaufmann J, Franke FC, Sperlich A, Blumendeller C, Kloos I, Schneider B, Sasaki D, Janssen KP, Beer-Hammer S. Jaufmann J, et al. FASEB J. 2021 Apr;35(4):e21470. doi: 10.1096/fj.202002495R. FASEB J. 2021. PMID: 33710696 Review.
Cited by
- miR-1238 inhibits cell proliferation by targeting LHX2 in non-small cell lung cancer.
Shi X, Zhan L, Xiao C, Lei Z, Yang H, Wang L, Zhao J, Zhang HT. Shi X, et al. Oncotarget. 2015 Aug 7;6(22):19043-54. doi: 10.18632/oncotarget.4232. Oncotarget. 2015. PMID: 26189214 Free PMC article. - SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype.
Shellman YG, Lambert KA, Brauweiler A, Fain P, Spritz RA, Martini M, Janssen KP, Box NF, Terzian T, Rewers M, Horvath A, Stratakis CA, Robinson WA, Robinson SE, Norris DA, Artinger KB, Pacheco TR. Shellman YG, et al. J Invest Dermatol. 2015 Dec;135(12):3192-3194. doi: 10.1038/jid.2015.292. Epub 2015 Jul 23. J Invest Dermatol. 2015. PMID: 26203640 Free PMC article. No abstract available. - SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.
Burgess JT, Bolderson E, Saunus JM, Zhang SD, Reid LE, McNicol AM, Lakhani SR, Cuff K, Richard K, Richard DJ, O'Byrne KJ. Burgess JT, et al. Oncotarget. 2016 Nov 8;7(45):72807-72818. doi: 10.18632/oncotarget.12020. Oncotarget. 2016. PMID: 27637080 Free PMC article. - _NORAD_-Regulated Signaling Pathways in Breast Cancer Progression.
Capela AM, Tavares-Marcos C, Estima-Arede HF, Nóbrega-Pereira S, Bernardes de Jesus B. Capela AM, et al. Cancers (Basel). 2024 Feb 1;16(3):636. doi: 10.3390/cancers16030636. Cancers (Basel). 2024. PMID: 38339387 Free PMC article. Review. - HMGB1 contributes to SASH1 methylation to attenuate astrocyte adhesion.
Wu R, Yan Y, Ma C, Chen H, Dong Z, Wang Y, Liu Y, Liu M, Yang L. Wu R, et al. Cell Death Dis. 2019 May 28;10(6):417. doi: 10.1038/s41419-019-1645-7. Cell Death Dis. 2019. PMID: 31138780 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials